Top-News
Sonstige Kanada

Theratechnologies News

Aktie
WKN:  A3ERKM ISIN:  CA88338H7040 US-Symbol:  THTX
1,13 €
+0,04 €
+3,67%
21:11:02 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
23,46 Mio.
Marktkapitalisierung *
25,44 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 31.07.2023

Theratechnologies News

04.10.17 - PR Newswire
Theratechnologies Announces 48-Week Efficacy and Safety Results for Ibalizumab Presented at IDWeek 2017™
Theratechnologies Announces 48-Week Efficacy and Safety Results for Ibalizumab Presented at IDWeek 2017™ HIV Monoclonal Antibody and Long-​Acting Investigational Antiretroviral ...
24.07.17 - PR Newswire
Theratechnologies Announces New Findings with the Investigational Antiretroviral Ibalizumab and with EGRIFTA® (tesamorelin for injection)
Theratechnologies Announces New Findings with the Investigational Antiretroviral Ibalizumab and with EGRIFTA® (tesamorelin for injection) Results Presented at 9th IAS ...
03.05.17 - PR Newswire
Theratechnologies Partner Submits Biologics License Application for HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab
Theratechnologies Partner Submits Biologics License Application for HIV Monoclonal Antibody and Long-​Acting Investigational Antiretroviral Ibalizumab Potential New Treatment ...
15.02.17 - PR Newswire
Theratechnologies Announces Comparative PK Data on the Intramuscular and Intravenous Administration of the Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab
Theratechnologies Announces Comparative PK Data on the Intramuscular and Intravenous Administration of the Monoclonal Antibody and Long-​Acting Investigational Antiretroviral ...
14.02.17 - PR Newswire
Theratechnologies Announces New Data from the Pivotal Phase III Trial of HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab
Theratechnologies Announces New Data from the Pivotal Phase III Trial of HIV Monoclonal Antibody and Long-​Acting Investigational Antiretroviral Ibalizumab Ibalizumab Maintains ...
15.11.16 - PR Newswire
IIROC Trade Resumption - TH; AVO
IIROC Trade Resumption - TH; AVO Canada NewsWire
14.11.16 - PR Newswire
IIROC Trading Halt - TH
IIROC Trading Halt - TH Canada NewsWire
10.11.16 - PR Newswire
Theratechnologies Announces Results from the Last Pivotal Phase III Trial of HIV Long Acting Biologic (LAB) Investigational Antiretroviral Ibalizumab.
Theratechnologies Announces Results from the Last Pivotal Phase III Trial of HIV Long Acting Biologic (LAB) Investigational Antiretroviral Ibalizumab. Ibalizumab Maintains ...
28.10.16 - PR Newswire
Results of HIV Biologic and Long-Acting Investigational Antiretroviral Ibalizumab to be Presented in Late-Breaker Session at IDWeek 2016™
Results of HIV Biologic and Long-​Acting Investigational Antiretroviral Ibalizumab to be Presented in Late-​Breaker Session at IDWeek 2016™ Phase III Study Primary Endpoint Results ...
06.08.15 - PR Newswire
IIROC Trade Resumption - TH.WT
IIROC Trade Resumption - TH.WT Canada NewsWire
06.08.15 - PR Newswire
IIROC Trading Halt - TH.WT
IIROC Trading Halt - TH.WT Canada NewsWire
13.12.13 - PR Newswire
IIROC Trade Resumption - TH
IIROC Trade Resumption - TH Canada NewsWire
16.07.12 - Aktiencheck
Theratechnologies-Aktie: "buy" - Canaccord Genuity
Neil Maruoka, Analyst von Canaccord Genuity, stuft die Aktie von Theratechnologies weiterhin mit dem Votum "buy" ein. Das 12-Monats-​Kursziel werde nach wie vor bei 4,00 CAD ...
31.05.11 - Aktiencheck
Theratechnologies Egrifta sorgt für Kursfantasie - Global Biotech Investing
Die Experten von "Global Biotech Investing" halten die Aktie von Theratechnologies für spekulativ veranlagte Anleger für interessant. Der Titel habe sich von seinem Kurssturz vom ...
05.07.10 - Aktiencheck
Theratechnologies gute Chancen für FDA-Zulassung - Global Biotech Investing
Nach Meinung der Experten von "Global Biotech Investing" sollen sich weitsichtige Anleger eine Startposition der Theratechnologies-​Aktie ins Depot legen. Ende Mai sei es bei dem ...
28.10.03 - Aktiencheck
Theratechnologies Kaufempfehlung - Global Biotech Investing
05.05.03 - Aktiencheck
Theratechnologies aussichtsreich - Global Biotech Investing

Newssuche

Videos

09:05 Uhr
Technical Trading: DAX dienstags Long
DAX Long Typ: Turbo Open End WKN: NG8K9X Hebel: 26 Laufzeit: OpenEnd Einstieg: Market ... Mehr »